©2024 Stanford Medicine
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Not Recruiting
Trial ID: NCT01306890
Purpose
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs)
following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
Official Title
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- subjects must be at least 18 years of age
- subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent
their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to
enrollment
- subjects must understand and sign an informed consent form
Exclusion Criteria:
- none
Intervention(s):
biological: sipuleucel-T
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Denise Haas
6507361252